Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04691388 | A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor | completed | Phase 2 | 29 | Zhejiang Cancer HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03081689 | Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients | completed | Phase 2 | 46 | Spanish Lung Cancer GroupOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03134456 |
| Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX |
| completed |
| Phase 4 |
| 50 |
| Samsung Medical CenterOTHER |
| 1 |
| Dec 3, 2024 |
| clinicaltrials |
| NCT04629300 | Supportive Care Mobile Application for Patients With NSCLC | completed | N/A | 120 | Massachusetts General HospitalOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT02135679 | The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy | completed | — | 204 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02613507 | Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer(CheckMate 078) | completed | Phase 3 | 504 | Bristol-Myers SquibbINDUSTRY | 4 | Nov 19, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02113813 | A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 1 | 133 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05807893 | Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases(SUPER BRAIN) | completed | Phase 2 / Phase 3 | 40 | Sun Yat-sen UniversityOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT04416633 | Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC | completed | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT02488850 | Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage NSCLC(HAMLET) | completed | N/A | 32 | Erasmus Medical CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04920981 | Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC(CLINATEZO) | completed | — | 518 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05898763 | TEIPP Immunotherapy in Patients With NSCLC(TEIPP) | completed | Phase 1 / Phase 2 | 26 | Erasmus Medical CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT02094261 | Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours(AURA2) | completed | Phase 2 | 210 | AstraZenecaINDUSTRY | 8 | Nov 6, 2024 | clinicaltrials |
| NCT04504669 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | completed | Phase 1 | 60 | AstraZenecaINDUSTRY | 4 | Nov 5, 2024 | clinicaltrials |
| NCT04702607 | Functional Lung Imaging With DECT and 4DCT | completed | — | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05347797 | Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit | completed | N/A | 495 | QIAGEN Gaithersburg, IncINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05348187 | Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit | completed | N/A | 309 | QIAGEN Gaithersburg, IncINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05360225 | Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit | completed | — | 5,000 | QIAGEN Gaithersburg, IncINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05304793 | Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer | completed | N/A | 46 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT03594747 | A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer | completed | Phase 3 | 360 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT04952597 | Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer | completed | Phase 2 | 126 | BeiGeneINDUSTRY | 3 | Oct 26, 2024 | clinicaltrials |
| NCT01725165 | Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 85 | M.D. Anderson Cancer CenterOTHER | 2 | Oct 24, 2024 | clinicaltrials |
| NCT03486730 | BT1718 in Patients with Advanced Solid Tumours. | completed | Phase 1 / Phase 2 | 72 | Cancer Research UKOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03191786 | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy(IPSOS) | completed | Phase 3 | 453 | Hoffmann-La RocheINDUSTRY | 24 | Oct 23, 2024 | clinicaltrials |
| NCT03217071 | Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer | completed | Phase 2 | 12 | Sue YomOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT03293680 | Pembrolizumab in Elderly Patients With Advanced Lung Cancer | completed | Phase 2 | 83 | Spanish Lung Cancer GroupOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT04843007 | Alvopem® (Pemetrexed) Safety Assessment | completed | — | 199 | NanoAlvandINDUSTRY | 0 | Oct 23, 2024 | clinicaltrials |
| NCT03958045 | Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | completed | Phase 2 | 33 | Zhonglin HaoOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT04007068 | FDG PET/CT Radiomics Analyses of Lung Cancer Patients Treated With Immunotherapy | completed | — | 30 | Institute of Oncology LjubljanaOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT02364609 | Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib | completed | Phase 1 | 11 | Jonathan RiessOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT03004183 | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC(STOMP) | completed | Phase 2 | 57 | The Methodist Hospital Research InstituteOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05383898 | Study to Evaluate D-1553 in Subjects With Lung Cancer | completed | Phase 1 / Phase 2 | 225 | InventisBio Co., LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06313268 | Safety of Effivia®, a Bevacizumab Biosimilar | completed | — | 83 | Laboratorios LiomontINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT02955758 | Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer | completed | Phase 2 | 25 | Joel NealOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT03526900 | Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis(ATEZO-BRAIN) | completed | Phase 2 | 40 | Spanish Lung Cancer GroupOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT02775435 | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | completed | Phase 3 | 559 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 8, 2024 | clinicaltrials |
| NCT03583086 | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | completed | Phase 1 / Phase 2 | 88 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03822351 | Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC(COAST) | completed | Phase 2 | 189 | MedImmune LLCINDUSTRY | 9 | Oct 8, 2024 | clinicaltrials |
| NCT01899989 | Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer | completed | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT05569291 | Investigating the Feasibility of a Physical Activity (tele)coaching Intervention in Patients with Non-small Cell Lung Cancer: an Explorative Study(LUCA-coach) | completed | N/A | 19 | Hasselt UniversityOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT01306045 | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | completed | Phase 2 | 647 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03875092 | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study | completed | Phase 3 | 125 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03718117 | Descriptive Observational Study ALK-2016-CPHG(ALK2016CPHG) | completed | — | 73 | PfizerINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT04768296 | Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) | completed | Phase 2 | 76 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 7 | Sep 26, 2024 | clinicaltrials |
| NCT02264210 | Icotinib for Completed Resected IB NSCLC With EGFR Mutation(CORIN) | completed | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT03565003 | A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China | completed | Phase 1 / Phase 2 | 126 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 5, 2024source: clinicaltrials